Novartis’ radiopharma gambit; Weight loss battle plays out; Spark co-founder’s new startup; Q1 earnings highlights; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We are less than two weeks away from the US Phar­ma and Biotech Sum­mit, where we part­ner with the Fi­nan­cial Times to in­ter­view bio­phar­ma lead­ers, reg­u­la­tors, in­vestors and sci­en­tists for unique in­sights about the year ahead. Learn more and sign up here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.